1. Pink Sheet
  2. >>Geography
  3. >>International

CEPI Expands COVID-19 Vaccine Portfolio, But Pleads For Big Funding Boost

Six Programs Now Under Way

 
• By Ian Schofield

As the coronavirus continues its global spread, the global CEPI partnership is broadening its investment in programs that it hope will result in the rapid development and licensing of new vaccines.

Covid_2019_Vaccine
Resources are being mobilized at global level to develop a COVID-19 vaccine • Source: Shutterstock

The international Coalition for Epidemic Preparedness Innovations has increased its COVID-19 vaccine candidate portfolio from four to six after it signed partnership deals worth a total of US$4.4m with Novavax and the University of Oxford in the UK. 

However, CEPI is running low on money and has launched an appeal for an additional $2bn in funding for coronavirus vaccine development, saying that without immediate financial contributions from donors it will not

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from International

More from Geography

EU Pharma Reform: Exclusivity Vouchers Alone Are Insufficient Incentive For Antimicrobials, Industry Says

 
• By Eliza Slawther

European pharma trade associations EFPIA and EUCOPE outline their respective views on how the EU’s pharma legislation overhaul should tackle antimicrobial resistance, and why transferable exclusivity vouchers alone will not suffice as incentives.

Trump Administration Push For Dismissal, Transfer Of Mifepristone Case Leaves Overhang For Pharma

 
• By Sarah Karlin-Smith

The Trump Administration requested a dismissal or transfer of a lawsuit seeking to tighten the safety requirements for the abortion pill mifepristone on procedural grounds, which still leaves the administration's position on the case's merits unclear.

Opioid Safety: US FDA Hears Mixed Messages On Adding Posmarketing Studies To Labeling

 
• By Sue Sutter

Some advisory committee members said adding quantitative data on misuse, abuse, opioid use disorder and overdose to labeling would be helpful, but others worried the two epidemiological studies were not sufficiently generalizable to a broader population.